CA2012852A1 - Methode d'inhibition des spasmes des vaisseaux et de l'aggregation des plaquettes resultant d'une angioplastie a l'aide d'antagonistes des recepteurs de la thromboxane a - Google Patents

Methode d'inhibition des spasmes des vaisseaux et de l'aggregation des plaquettes resultant d'une angioplastie a l'aide d'antagonistes des recepteurs de la thromboxane a

Info

Publication number: CA2012852A1
Authority: CA; Canada
Prior art keywords: thromboxane; lower alkyl; alpha; receptor antagonist; amino
Prior art date: 1989-05-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002012852A

Other languages

English (en)

Inventor

Miguel A. Ondetti

Martin L. Ogletree

Don N. Harris

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-05-01

Filing date

1990-03-22

Publication date

1990-11-01

1990-03-22 Application filed by Individual filed Critical Individual

1990-11-01 Publication of CA2012852A1 publication Critical patent/CA2012852A1/fr

Status Abandoned legal-status Critical Current

Links

238000002399 angioplasty Methods 0.000 title claims abstract description 28
238000000034 method Methods 0.000 title claims abstract description 26
206010047163 Vasospasm Diseases 0.000 title claims abstract description 23
208000010110 spontaneous platelet aggregation Diseases 0.000 title claims abstract description 18
230000002401 inhibitory effect Effects 0.000 title claims abstract description 14
239000002464 receptor antagonist Substances 0.000 title abstract description 12
229940044551 receptor antagonist Drugs 0.000 title abstract description 12
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 title description 3
-1 7-oxabicycloheptane prostaglandin Chemical class 0.000 claims abstract description 29
239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims abstract description 27
229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims abstract description 24
125000000217 alkyl group Chemical group 0.000 claims description 32
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
125000003118 aryl group Chemical group 0.000 claims description 14
DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 7
125000003710 aryl alkyl group Chemical group 0.000 claims description 7
125000003342 alkenyl group Chemical group 0.000 claims description 4
125000003282 alkyl amino group Chemical group 0.000 claims description 4
125000000304 alkynyl group Chemical group 0.000 claims description 4
125000001691 aryl alkyl amino group Chemical group 0.000 claims description 4
125000001769 aryl amino group Chemical group 0.000 claims description 4
125000004104 aryloxy group Chemical group 0.000 claims description 4
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
125000004076 pyridyl group Chemical group 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
229910052783 alkali metal Inorganic materials 0.000 claims description 2
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims description 2
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
125000005128 aryl amino alkyl group Chemical group 0.000 claims description 2
125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
125000000547 substituted alkyl group Chemical group 0.000 claims description 2
150000003536 tetrazoles Chemical class 0.000 claims description 2
229940122202 Thromboxane receptor antagonist Drugs 0.000 claims 1
239000002396 thromboxane receptor blocking agent Substances 0.000 claims 1
102000003938 Thromboxane Receptors Human genes 0.000 abstract description 12
108090000300 Thromboxane Receptors Proteins 0.000 abstract description 12
210000001367 artery Anatomy 0.000 description 9
208000037803 restenosis Diseases 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000008021 deposition Effects 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
208000007536 Thrombosis Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000001732 thrombotic effect Effects 0.000 description 3
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000003902 lesion Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
239000003768 thromboxane synthase inhibitor Substances 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
108010003541 Platelet Activating Factor Proteins 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
229940099508 TP receptor antagonist Drugs 0.000 description 1
229940111979 Thromboxane synthase inhibitor Drugs 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
XQGZSYKGWHUSDH-UHFFFAOYSA-N dazoxiben Chemical compound C1=CC(C(=O)O)=CC=C1OCCN1C=NC=C1 XQGZSYKGWHUSDH-UHFFFAOYSA-N 0.000 description 1
229950008000 dazoxiben Drugs 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000001 effect on platelet aggregation Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000001114 myogenic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)

CA002012852A 1989-05-01 1990-03-22 Methode d'inhibition des spasmes des vaisseaux et de l'aggregation des plaquettes resultant d'une angioplastie a l'aide d'antagonistes des recepteurs de la thromboxane a Abandoned CA2012852A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34644789A	1989-05-01	1989-05-01
US346,447		1989-05-01

Publications (1)

Publication Number	Publication Date
CA2012852A1 true CA2012852A1 (fr)	1990-11-01

Family

ID=23359439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002012852A Abandoned CA2012852A1 (fr)	1989-05-01	1990-03-22	Methode d'inhibition des spasmes des vaisseaux et de l'aggregation des plaquettes resultant d'une angioplastie a l'aide d'antagonistes des recepteurs de la thromboxane a

Country Status (6)

Country	Link
JP (1)	JPH02295922A (fr)
CA (1)	CA2012852A1 (fr)
DE (1)	DE4013680A1 (fr)
FR (1)	FR2646351A1 (fr)
GB (1)	GB2231795A (fr)
IT (1)	IT1240681B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4687500A (en) *	1999-04-29	2000-11-17	Allergan Sales, Inc.	Thromboxane ligands without blood clotting side effects

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4537981A (en) *	1981-11-09	1985-08-27	E. R. Squibb & Sons, Inc.	7-Oxabicycloheptane and 7-oxabicycloheptene compounds
US4416896A (en) *	1982-05-17	1983-11-22	E. R. Squibb & Sons, Inc.	7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease
US4663336A (en) *	1985-07-01	1987-05-05	E. R. Squibb & Sons, Inc.	7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease

1990
- 1990-03-22 CA CA002012852A patent/CA2012852A1/fr not_active Abandoned
- 1990-04-26 IT IT20136A patent/IT1240681B/it active IP Right Grant
- 1990-04-27 DE DE4013680A patent/DE4013680A1/de not_active Withdrawn
- 1990-04-30 GB GB9009636A patent/GB2231795A/en not_active Withdrawn
- 1990-05-01 JP JP2116704A patent/JPH02295922A/ja active Pending
- 1990-05-02 FR FR9005547A patent/FR2646351A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
IT9020136A1 (it)	1991-10-26
FR2646351A1 (fr)	1990-11-02
DE4013680A1 (de)	1990-11-08
JPH02295922A (ja)	1990-12-06
GB2231795A (en)	1990-11-28
GB9009636D0 (en)	1990-06-20
IT9020136A0 (it)	1990-04-26
IT1240681B (it)	1993-12-17

Legal Events

Date	Code	Title	Description
1994-09-22	FZDE	Discontinued
2023-05-26	FZDE	Discontinued	Effective date: 19940922

Publication	Publication Date	Title
US6610732B2 (en)	2003-08-26	Anti-constipation composition
US5001154A (en)	1991-03-19	Fervescence composition
CA1336686C (fr)	1995-08-15	Methode de prevention ou de traitement des migraines au moyen d'un antagoniste du recepteur de la thromboxane a
US4931460A (en)	1990-06-05	Post-ischemic myocardial dysfunction using thromboxane A2 antagonists
US5221690A (en)	1993-06-22	Increasing the choroidal blood flow
GB2231795A (en)	1990-11-28	Inhibiting vasospasm and platelet aggregation resulting from angioplasty using a thromboxane A2 receptor antagonist
US5523321A (en)	1996-06-04	Prostacyclins, their analogs or prostaglandins and thromboxane antagonists for treatment of thrombotic and thromboembolic syndromes
HU208493B (en)	1993-11-29	Process for producing pharmaceutical composition for treating and preventing vein thrombosis
US4975279A (en)	1990-12-04	Method of improving post-ischemic myocardial function using a thromboxane A2 antagonist in combination with a thrombolytic agent and combination
IE59338B1 (en)	1994-02-09	Prostacyclins, their analogues or prostaglandins and thromboxane antagonists for the treatment of thrombotic and thrombo-embolic syndromes
CZ291534B6 (cs)	2003-03-12	Použití prostanových derivátů a kombinace těchto látek s antibiotiky pro léčení bakteriálních infekcí
EP0474438A1 (fr)	1992-03-11	Méthode pour la prévention et le traitement de maladies cérébrovasculaires en utilisant l'inhibiteur de l'enzyme de conversion de l'angiotensine céranapril
NZ232110A (en)	1997-03-24	Pharmaceutical compositions containing a 7-oxa-bicycloheptane prostaglandin analogue as a thrombane a2 receptor antagonist
CZ288219B6 (en)	2001-05-16	Medicament for prophylaxis or therapy of restenosis
US3895114A (en)	1975-07-15	Cyclic hydroxamic acids as antihypertensive agents
JPH0296529A (ja)	1990-04-09	眼圧降下剤
NZ226198A (en)	1991-05-28	Fervescence (temperature raising) composition comprising 15-keto-pge
GB2227664A (en)	1990-08-08	Treating hypertension using a thromboxane A2 receptor antagonist
JPWO1992012968A1 (ja)	1993-02-04	血栓用医薬組成物
EP0342030A2 (fr)	1989-11-15	Utilisation d'un antagoniste du récepteur du tromboxane pour compléter la chirurgie artérielle
GB2219938A (en)	1989-12-28	Use of a thromboxane receptor antagonist in pregnancy-induced hypertension
GB2219939A (en)	1989-12-28	Use of a thromboxane receptor antagonist in renal diseases and dysfunction
JPH05279253A (ja)	1993-10-26	骨粗鬆症予防および治療剤